Prostate cancer
Drug research and approvals for prostate cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,229 studies of prostate cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 219 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 17 authorised medicines for it.
- Recruiting worldwide: 1,229
- Trials authorized in Canada: 219
- FDA orphan approvals: 1
- EU medicines: 17
- DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate CancerNCT07950501 · Not applicable · Mahidol University · starts Jun 2, 2026
- A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery:NCT07950722 · Not applicable · Chinese University of Hong Kong · starts Nov 1, 2026
- Ultra-hypofractionated radiotHErapy and Concomitant Oral RelugOlix for Treatment of Intermediate Risk Prostate Cancer.NCT07947745 · Not applicable · Azienda Ospedaliero-Universitaria Careggi · starts Jun 18, 2025
- Deep Rectus Sheath Block for Postoperative Pain in Laparoscopic Radical ProstatectomyNCT07948902 · Not applicable · Marmara University Pendik Training and Research Hospital · starts Nov 16, 2026
- A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled…NCT07944508 · Phase 1 · MultiValent Biotherapies, Inc. · starts Aug 14, 2026
- A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid TumorsNCT07945821 · Phase 1 / Phase 2 · Coherus Oncology, Inc. · starts Nov 1, 2026
- Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission TomographyNCT07940179 · Not applicable · Jean-Mathieu Beauregard · starts Nov 4, 2021
- Virtual Reality Education Before CyberKnife Treatment for Prostate CancerNCT07932626 · Not applicable · University Hospital Ostrava · starts Aug 1, 2026
- Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional…NCT07910019 · Not reported · Masonic Cancer Center, University of Minnesota · starts Oct 8, 2026
Approved 24 of 27
- DocetaxelTubulin inhibitor
- CabazitaxelCastration-resistant prostate cancer · Tubulin inhibitor
- ApalutamideCastration-resistant prostate cancer · Androgen Receptor antagonist
- EnzalutamideAndrogen Receptor antagonist
- DarolutamideCastration-resistant prostate cancer · Androgen Receptor antagonist
- LeuprolideGonadotropin-releasing hormone receptor agonist
- Sipuleucel-tCastration-resistant prostate cancer · Prostatic acid phosphatase binding agent
- OlaparibCastration-resistant prostate cancer · PARP 1, 2 and 3 inhibitor
- Vipivotide tetraxetan lutetiumCastration-resistant prostate cancer · Glutamate carboxypeptidase II binding agent
- DegarelixGonadotropin-releasing hormone receptor antagonist
- Radium dichlorideRadiotherapy agent
- FlutamideAndrogen Receptor antagonist
- RelugolixGonadotropin-releasing hormone receptor antagonist
- DutasterideSteroid 5-alpha-reductase inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- NilutamideAndrogen Receptor antagonist
- PiflufolastatDiagnostic agent
- HistrelinGonadotropin-releasing hormone receptor agonist
- FluciclovineDiagnostic agent
- FinasterideSteroid 5-alpha-reductase 2 inhibitor
- CholineDiagnostic agent
- LidocaineSodium channel alpha subunit blocker
- TamsulosinAdrenergic receptor alpha-1 antagonist
Phase 3 12 of 90
- PrednisoneCastration-resistant prostate cancer · Glucocorticoid receptor agonist
- BicalutamideCastration-resistant prostate cancer · Androgen Receptor antagonist
- AbirateroneCastration-resistant prostate cancer · Cytochrome P450 17A1 inhibitor
- GoserelinCastration-resistant prostate cancer · Gonadotropin-releasing hormone receptor agonist
- PaclitaxelCastration-resistant prostate cancer · Tubulin inhibitor
- CarboplatinCastration-resistant prostate cancer · DNA inhibitor
- NivolumabCastration-resistant prostate cancer · Programmed cell death protein 1 inhibitor
- IpilimumabCastration-resistant prostate cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
- PembrolizumabCastration-resistant prostate cancer · Programmed cell death protein 1 inhibitor
- GozetotideCastration-resistant prostate cancer · Diagnostic agent
- DexamethasoneCastration-resistant prostate cancer · Glucocorticoid receptor agonist
- KetoconazoleCastration-resistant prostate cancer · Cytochrome P450 51 inhibitor
Phase 2 12 of 296
- CyclophosphamideCastration-resistant prostate cancer · DNA inhibitor
- SargramostimCastration-resistant prostate cancer · Granulocyte-macrophage colony-stimulating factor receptor agonist
- CelecoxibCastration-resistant prostate cancer · Cyclooxygenase-2 inhibitor
- Testosterone cypionateCastration-resistant prostate cancer · Androgen Receptor agonist
- CabozantinibCastration-resistant prostate cancer · Vascular endothelial growth factor receptor 2 inhibitor
- GefitinibCastration-resistant prostate cancer · Epidermal growth factor receptor erbB1 inhibitor
- SorafenibCastration-resistant prostate cancer · Serine/threonine-protein kinase RAF inhibitor
- DurvalumabCastration-resistant prostate cancer · Programmed cell death 1 ligand 1 inhibitor
- IxabepiloneCastration-resistant prostate cancer · Tubulin inhibitor
- VinorelbineCastration-resistant prostate cancer · Tubulin inhibitor
- TestosteroneCastration-resistant prostate cancer · Androgen Receptor agonist
- ImatinibCastration-resistant prostate cancer · Tyrosine-protein kinase ABL inhibitor
Phase 1 or earlier 12 of 170
- FludarabineCastration-resistant prostate cancer
- MidazolamCastration-resistant prostate cancer · GABA-A receptor; anion channel positive allosteric modulator
- RimiducidCastration-resistant prostate cancer
- HiltonolCastration-resistant prostate cancer
- NezastomigCastration-resistant prostate cancer
- SonidegibCastration-resistant prostate cancer · Smoothened homolog inhibitor
- TemozolomideDNA inhibitor
- VismodegibCastration-resistant prostate cancer · Smoothened homolog inhibitor
- AZD3514Castration-resistant prostate cancer · Androgen Receptor modulator
- CC-115Castration-resistant prostate cancer · Serine/threonine-protein kinase mTOR inhibitor
- DactolisibCastration-resistant prostate cancer · Serine/threonine-protein kinase mTOR inhibitor
- PicoplatinCastration-resistant prostate cancer · DNA cross-linking agent
How its trials ended
5,809 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,321 whose ending is known, 28% met their primary endpoint, 9% missed it and 63% stopped early.
- Completed, result not reported2,23739%
- Ongoing1,65128%
- Status unknown60010%
- Stopped: other or unclear4147%
- Met its primary endpoint3666%
- Stopped: enrollment or feasibility2234%
- Missed its primary endpoint1222%
- Stopped: sponsor or business decision781%
- Stopped: lack of efficacy681%
- Stopped: funding331%
- Stopped: safety17<1%
| Nov 6, 2026 | A phase 1 open-label, multicenter study to evaluate the safety, tolerability and pharmacokinetics of MK-1568 as monotherapy in participants with metastatic…MK-1568 | Merck & Co. (MSD) | Pending |
| Oct 23, 2026 | Master protocol: MK-2870-U01 master protocol: a phase 1/2 platform study to evaluate the safety and efficacy of sacituzumab tirumotecan (sac-tmt; MK-2870) as…MK-2870 (sacituzumab tirumotecan) / Opevesostat (MK-5684) / Abiraterone acetate… | Merck & Co. (MSD) | Pending |
| Oct 9, 2026 | Actfirst: a phase III, open-label, multi-center, randomized study comparing AAA817+arpi versus standard of care in adult participants with psma-positive…[225AC]AC-PSMA-617 (AAA817) / Zytiga / Xtandi | Novartis Pharmaceuticals | Pending |
| Sep 25, 2026 | A phase 3, open-label study of risvutatug rezetecan versus docetaxel in participants with metastatic, chemo-naïve androgen pathway modulator-resistant prostate…Risvutatug rezetecan (GSK5764227) | GSK | Pending |
| Sep 24, 2026 | A phase 2, open-label platform study utilizing a master protocol to study risvutatug rezetecan as monotherapy or in combination with other treatments in adult…Risvutatug rezetecan (GSK5764227) | GSK | Pending |
| Aug 4, 2026 | A phase 3, randomized, open-label study of rinzimetostat (ORIC-944) in combination with darolutamide compared with arpi or docetaxel in patients with…Rinzimetostat (ORIC-944) / Darolutamide | Oric Pharmaceuticals | Pending |
| Jul 28, 2026 | Psmaction: a phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants…[225AC]AC-PSMA-617 (AAA817) | Novartis Pharmaceuticals | Pending |
| Jul 23, 2026 | A phase 3 randomized study to evaluate the safety and efficacy of risvutatug rezetecan, a B7-H3 antibody drug conjugate (ADC) in participants with metastatic…Risvutatug rezetecan (GSK5764227) | GSK | Ongoing |
| Jul 15, 2026 | A randomized, double-blind, placebo-controlled, 2-cohort, phase III study of saruparib combined with physician’s choice of androgen receptor pathway inhibitor…Saruparib (AZD5305) / Darolutamide | AstraZeneca Pharmaceuticals | Ongoing |
| Jun 19, 2026 | A phase I, open-label, multicenter study of JANX007 in subjects with metastatic castration resistant prostate cancerJANX007 | Janux Therapeutics | Pending |
| Nov 13, 1996 | NovantroneIn combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory… | Serono | Approved |
| Jun 6, 2026 | PembrolizumabTreatment of neuroendocrine prostate cancer (NEPC) | Merck, Sharp & Dohme LLC. | Designated |
| May 6, 1997 | SuraminTreatment of hormone-refractory prostate cancer. | Warner-Lambert Company | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA